Program
albenatide
Also written as “CJC-1134-PC Injection” and “CJC-1134-PC”.
Its studies are mostly in Diabetes Mellitus, Type 2, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) | 20 open or running | phase 3since Jun 18, 2025 | Jun 18, 2025 | none ahead |
| ConjuChem | 20 open or running | phase 2since Mar 13, 2008 | Mar 13, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 13, 2008First study: phase 2 study in Diabetes Mellitus, Type 2New to ConjuChemConjuChem · NCT00638716 · 122 enrolled · Canada
- Oct 20, 2011Phase 2 study in Diabetes Mellitus, Type 2ConjuChem · NCT01514149 · 73 enrolled · United States, Canada
- Jun 18, 2025Changshan ConjuChem BioPharmaceutical Research and Development (Hebei)'s first studies: 2 phase 3 studies in Type 2 Diabetes Mellitus - Poor ControlNew to Changshan ConjuChem BioPharmaceutical Research and Development (Hebei)Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) · NCT07058545, NCT07057271
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07057271Type 2 Diabetes Mellitus - Poor Control · China | 3 | Completed | Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) | Feb 21, 2023 | 464 |
| NCT07058545Type 2 Diabetes Mellitus - Poor Control · China | 3 | Completed | Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) | Feb 20, 2023 | 474 |
| NCT01514149Diabetes Mellitus, Type 2 · United States, Canada | 2 | Terminated | ConjuChem | May 2012 | 73 |
| NCT00638716Diabetes Mellitus, Type 2 · Canada | 2 | Completed | ConjuChem | Nov 2008 | 122 |
How it is read
Names in the registry
- “CJC-1134-PC Injection”, 3 entries
- “CJC-1134-PC”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.